Oppenheimer Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23
Y-mAbs Therapeutics Analyst Ratings
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Institutional Investors Lost 13% Last Week but Have Benefitted From Longer-term Gains